Provident Investment Management, Inc. Biogen Inc. Transaction History

Provident Investment Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 13, 2019	SELL	$216.71 - $338.96 $17.8 Million - $27.8 Million	-82,099 Closed	0 $0
Q4 2018 Feb 11, 2019	SELL	$278.5 - $352.75 $713,517 - $903,745	-2,562 Reduced 3.03%	82,099 $24.7 Million
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $735,242 - $961,494	-2,505 Reduced 2.87%	84,661 $29.9 Million
Q2 2018 Aug 09, 2018	BUY	$257.52 - $306.91 $1.12 Million - $1.33 Million	4,336 Added 5.23%	87,166 $25.3 Million
Q1 2018 Apr 23, 2018	BUY	$260.13 - $367.91 $4.13 Million - $5.84 Million	15,874 Added 23.71%	82,830 $22.7 Million
Q4 2017 Feb 06, 2018	BUY	$307.64 - $344.58 $145,206 - $162,641	472 Added 0.71%	66,956 $21.3 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $18.7 Million - $21.9 Million	66,484	66,484 $20.8 Million

1,015

126M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.3B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Provident Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Provident Investment Management, Inc. with notifications on news.